Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy

Figures & data

Table 1. Baseline characteristics of CHRYSALIS and LC-SCRUM-Asia EC patients with (weighted) and without propensity score matching (unweighted).

		LC-SCRUM-Asia N = 94
	CHRYSALIS N = 115	Unweighted	Weighted	p-Value*
Number of LOTs	115	309	114.6	–
Age (years)				0.258
Mean (SD)	61.6 (10.1)	60.3 (10.9)	61.4 (6.5)
Sex (%)				0.759
Female	70 (60.9)	183 (59.2)	68 (59.7)
Male	45 (39.1)	126 (40.8)	46 (40.3)
Race (%)				–
Asian	61 (53.0)	309 (100.0)	–
Black/African American	2 (1.7)	0 (0.00)
White	42 (36.5)	0 (0.00)
Missing	10 (8.8)	0 (0.00)
Smoking history (%)				0.856
Yes	48 (41.7)	132 (42.7)	49 (42.6)
No	67 (58.3)	177 (57.3)	66 (57.4)
Prior number of LOTs (%)				<0.001
1	49 (42.6)	78 (25.2)	48 (42.3)
2	34 (29.6)	73 (23.6)	34 (29.5)
3+	32 (27.8)	158 (51.1)	32 (28.2)

LOTs: lines of therapy; SD: standard deviation.

* P-value was calculated comparing data from CHRYSALIS patients with unweighted data from EC patients.

Table 2. Treatment patterns of LC-SCRUM EC patients in post-platinum lines by each LOT.

	All LOTs	First LOT	Second LOT	Third LOT
Total number of lines	309	94	76	60
Docetaxel (%)	68 (22.0%)	30 (31.9%)	24 (31.6%)	8 (13.3%)
Immuno-oncology (%)	67 (21.7%)	17 (18.1%)	19 (25.0%)	17 (28.3%)
EGFR TKIs (%)	59 (19.1%)	17 (18.1%)	13 (17.1%)	10 (16.7%)
Platinum-based therapy (%)	39 (12.6%)	18 (19.1%)	9 (11.8%)	3 (5.0%)
Others (%)	76 (24.6%)	12 (12.8%)	11 (14.5%)	22 (36.7%)

LOT: line of therapy.

Figure 1. KM curves for amivantamab-treated CHRYSALIS and LC-SCRUM-Asia EC patients for (a) overall survival (OS), (b) progression-free survival (PFS), and (c) time to next therapy (TTNT). *NE: Not evaluable.

Table 3. Baseline characteristics of Asian CHRYSALIS and LC-SCRUM-Asia EC patients with (weighted) and without propensity score matching (unweighted).

		LC-SCRUM-Asia N = 94
	Asian CHRYSALIS N = 61	Unweighted	Weighted	p-Value*
Number of LOTs	61	309	61.0	–
Age (years)				0.909
Mean (SD)	60.1 (10.2)	60.3 (10.9)	59.9 (4.9)
Sex (%)				0.976
Female	36 (59.0)	183 (59.2)	35 (57.6)
Male	25 (41.0)	126 (40.8)	26 (42.4)
Smoking history (%)				0.468
Yes	23 (37.7)	132 (42.7)	23 (38.2)
No	38 (62.3)	177 (57.3)	38 (61.8)
Prior number of LOTs (%)				0.048
1	24 (39.3)	78 (25.2)	24 (39.3)
2	15 (24.6)	73 (23.6)	15 (24.6)
3+	22 (36.1)	158 (51.1)	22 (36.1)

LOTs: lines of therapy; SD: standard deviation.

* P-value was calculated comparing data from CHRYSALIS patients with unweighted data from EC patients.

Figure 2. KM curves for Asian CHRYSALIS and LC-SCRUM-Asia EC patients for (a) overall survival (OS), (b) progression-free survival (PFS), and (c) time to next therapy (TTNT). *NE: Not evaluable.

Data availability statement

Due to the nature of the research and due to ethical/legal/commercial restrictions, supporting data is not available.